Paper Details

  1. Home
  2. Paper Details

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.

Author: ChenJing, DingYiling, ShuYamin, ZhangQilin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Rucaparib is used to treat recurrent ovarian, fallopian tube, or primary peritoneal cancers. This study investigated the long-term safety of rucaparib using a real-world pharmacovigilance database.
Paper Details　
Original Abstract of the Article :
Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate rucaparib-associated a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416473/

データ提供：米国国立医学図書館（NLM）

Real-World Safety of Rucaparib: A Pharmacovigilance Study

The field of [pharmacovigilance] is essential for ensuring the safety of new medications. This study examines the safety of [rucaparib], a drug approved for treating [recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer], using a large, real-world database. The researchers analyzed [rucaparib]-associated [adverse events (AEs)] to identify potential safety concerns.

Monitoring Drug Safety

This study provides real-world evidence on the safety of [rucaparib], complementing information from clinical trials. The findings can help clinicians and patients make informed decisions about the use of this medication.

Ensuring Patient Safety

Understanding the potential [AEs] associated with [rucaparib] is crucial for ensuring patient safety. This research contributes to ongoing efforts to monitor the safety of medications and provide the best possible care for patients.

Dr. Camel's Conclusion

Just like a camel needs to be cautious in its desert environment, doctors and patients must be aware of the potential risks associated with medications. This study helps us understand the safety profile of [rucaparib], allowing for more informed and safe treatment decisions.

Date :
  1. Date Completed 2023-08-14
  2. Date Revised 2023-11-20
Further Info :

Pubmed ID

37568126

DOI: Digital Object Identifier

PMC10416473

Related Literature

Article Analysis
・Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.